202 related articles for article (PubMed ID: 29780014)
1. Evaluation of In vitro and In vivo Drug Efficacy Over Leishmania tropica: A Pilot Study.
Özbilgin A; Çavuş İ; Yıldırım A; Kaya T; Ertabaklar H
Turkiye Parazitol Derg; 2018 Mar; 42(1):11-19. PubMed ID: 29780014
[TBL] [Abstract][Full Text] [Related]
2. Comparison of
Özbilgin A; Çavuş İ; Kaya T; Yıldırım A; Harman M
Turkiye Parazitol Derg; 2020 Mar; 44(1):12-16. PubMed ID: 32212583
[TBL] [Abstract][Full Text] [Related]
3. Glucantime-resistant Leishmania tropica isolated from Iranian patients with cutaneous leishmaniasis are sensitive to alternative antileishmania drugs.
Hadighi R; Boucher P; Khamesipour A; Meamar AR; Roy G; Ouellette M; Mohebali M
Parasitol Res; 2007 Oct; 101(5):1319-22. PubMed ID: 17610079
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of meglumine antimoniate against L. tropica in a recently emerged focus of cutaneous leishmaniasis in Birjand, eastern Islamic Republic of Iran.
Karamian M; Bojd MS; Salehabadi A; Hemmati M; Barati DA
East Mediterr Health J; 2015 Jun; 21(4):280-6. PubMed ID: 26077523
[TBL] [Abstract][Full Text] [Related]
5. The effect of verapamil on in vitro susceptibility of promastigote and amastigote stages of Leishmania tropica to meglumine antimoniate.
Shokri A; Sharifi I; Khamesipour A; Nakhaee N; Fasihi Harandi M; Nosratabadi J; Hakimi Parizi M; Barati M
Parasitol Res; 2012 Mar; 110(3):1113-7. PubMed ID: 21847598
[TBL] [Abstract][Full Text] [Related]
6. Unresponsiveness to Glucantime treatment in Iranian cutaneous leishmaniasis due to drug-resistant Leishmania tropica parasites.
Hadighi R; Mohebali M; Boucher P; Hajjaran H; Khamesipour A; Ouellette M
PLoS Med; 2006 May; 3(5):e162. PubMed ID: 16605301
[TBL] [Abstract][Full Text] [Related]
7. Drug resistance in leishmaniasis: its implication in systemic chemotherapy of cutaneous and mucocutaneous disease.
Grogl M; Thomason TN; Franke ED
Am J Trop Med Hyg; 1992 Jul; 47(1):117-26. PubMed ID: 1322070
[TBL] [Abstract][Full Text] [Related]
8. Involvement of thiol metabolism in resistance to glucantime in Leishmania tropica.
Arana FE; Pérez-Victoria JM; Repetto Y; Morello A; Castanys S; Gamarro F
Biochem Pharmacol; 1998 Nov; 56(9):1201-8. PubMed ID: 9802332
[TBL] [Abstract][Full Text] [Related]
9. Stage-specific activity of pentavalent antimony against Leishmania donovani axenic amastigotes.
Ephros M; Bitnun A; Shaked P; Waldman E; Zilberstein D
Antimicrob Agents Chemother; 1999 Feb; 43(2):278-82. PubMed ID: 9925518
[TBL] [Abstract][Full Text] [Related]
10. Comparison of Intralesional Sodium Stibogluconate versus Intralesional Meglumine Antimoniate for the Treatment of Leishmania major Cutaneous Leishmaniasis.
Solomon M; Ollech A; Pavlotsky F; Barzilai A; Schwartz E; Baum S; Astman N
Acta Derm Venereol; 2024 Apr; 104():adv35089. PubMed ID: 38682801
[TBL] [Abstract][Full Text] [Related]
11. Expression analysis of activated protein kinase C gene (LACK1) in antimony sensitive and resistant Leishmania tropica clinical isolates using real-time RT-PCR.
Hajjaran H; Kazemi-Rad E; Mohebali M; Oshaghi MA; Khadem-Erfan MB; Hajaliloo E; Reisi Nafchi H; Raoofian R
Int J Dermatol; 2016 Sep; 55(9):1020-6. PubMed ID: 27336481
[TBL] [Abstract][Full Text] [Related]
12. Comparative proteomics study on meglumine antimoniate sensitive and resistant Leishmania tropica isolated from Iranian anthroponotic cutaneous leishmaniasis patients.
Hajjaran H; Azarian B; Mohebali M; Hadighi R; Assareh A; Vaziri B
East Mediterr Health J; 2012 Feb; 18(2):165-71. PubMed ID: 22571094
[TBL] [Abstract][Full Text] [Related]
13. In-vitro sensitivity of Pakistani Leishmania tropica field isolate against buparvaquone in comparison to standard anti-leishmanial drugs.
Jamal Q; Khan NH; Wahid S; Awan MM; Sutherland C; Shah A
Exp Parasitol; 2015 Jul; 154():93-7. PubMed ID: 25911243
[TBL] [Abstract][Full Text] [Related]
14. Glucantime resistant Leishmania promastigotes are sensitive to pentostam.
Moreira ES; Guerra JB; Petrillo-Peixoto Mde L
Rev Soc Bras Med Trop; 1992; 25(4):247-50. PubMed ID: 1340539
[TBL] [Abstract][Full Text] [Related]
15. [Determination of Antimony Resistance Mechanism of Leishmania tropica Causing Cutaneous Leishmaniasis in Turkey].
Özbilgin A; Zeyrek FY; Güray MZ; Çulha G; Akyar I; Harman M; Özbel Y; Ertabaklar H; Çavuş İ; Gündüz C
Mikrobiyol Bul; 2020 Jul; 54(3):444-462. PubMed ID: 32755520
[TBL] [Abstract][Full Text] [Related]
16. Meglumine antımoniate-TiO2@Ag nanoparticle combinations reduce toxicity of the drug while enhancing its antileishmanial effect.
Abamor ES; Allahverdiyev AM; Bagirova M; Rafailovich M
Acta Trop; 2017 May; 169():30-42. PubMed ID: 28111133
[TBL] [Abstract][Full Text] [Related]
17. [A comparative study between sodium stibogluconate BP 88R and meglumine antimoniate in the treatment of cutaneous leishmaniasis. I. The efficacy and safety].
Saldanha AC; Romero GA; Merchan-Hamann E; Magalhães AV; Macedo Vde O
Rev Soc Bras Med Trop; 1999; 32(4):383-7. PubMed ID: 10495667
[TBL] [Abstract][Full Text] [Related]
18. In vitro susceptibility to pentavalent antimony in Leishmania infantum strains is not modified during in vitro or in vivo passages but is modified after host treatment with meglumine antimoniate.
Carrió J; Portús M
BMC Pharmacol; 2002 May; 2():11. PubMed ID: 12019027
[TBL] [Abstract][Full Text] [Related]
19. Identification of antimony resistance markers in Leishmania tropica field isolates through a cDNA-AFLP approach.
Kazemi-Rad E; Mohebali M; Khadem-Erfan MB; Saffari M; Raoofian R; Hajjaran H; Hadighi R; Khamesipour A; Rezaie S; Abedkhojasteh H; Heidari M
Exp Parasitol; 2013 Oct; 135(2):344-9. PubMed ID: 23928349
[TBL] [Abstract][Full Text] [Related]
20. Role of residual Sb(III) in meglumine antimoniate cytotoxicity and MRP1-mediated resistance.
Dzamitika SA; Falcão CA; de Oliveira FB; Marbeuf C; Garnier-Suillerot A; Demicheli C; Rossi-Bergmann B; Frézard F
Chem Biol Interact; 2006 Apr; 160(3):217-24. PubMed ID: 16524568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
